BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05, Zacks reports. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The business had revenue of $180.29 million for the quarter, compared to analyst estimates of $165.67 million. During the same period in the previous year, the company posted $0.06 EPS. The company’s revenue was up 13.1% compared to the same quarter last year.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue was $174.8 million, up 20% year over year excluding Europe, but included an upper-teens-million-dollar, one-time contribution from CareMed’s inventory build. BioCryst kept its full-year ORLADEYO guidance at $625 million–$645 million, saying future revenue should more closely reflect patient demand.
• BioCryst reported non-GAAP operating profit of $86 million, up 70% year over year, and non-GAAP net income of $71 million, more than doubling. It raised total 2026 revenue guidance to $715 million–$730 million, tightened operating expense guidance to $415 million–$425 million, and expects restructuring actions to generate $30 million–$35 million in annualized savings.
• Management described ORLADEYO prescriptions and net patient additions as strong, with early pediatric demand ahead of expectations and potential to exceed the previously estimated 500-patient opportunity. The company also launched pediatric pellets and plans to offer a newly approved 150 mg pellet formulation for patients 12 and older.
• The navenibart pivotal trial is fully enrolled, with 12-month top-line data expected in the third quarter of 2027; BioCryst is also preparing its BLA and launch plans. The company expects early BCX17725 data in Netherton syndrome by year-end and is evaluating early-stage external opportunities, but said further investment and development decisions will depend on the data and scientific assessment.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded down $0.07 on Wednesday, hitting $8.49. The stock had a trading volume of 2,060,010 shares, compared to its average volume of 4,886,355. The stock’s 50 day moving average is $8.58 and its 200-day moving average is $8.74. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -5.66 and a beta of 0.55. BioCryst Pharmaceuticals has a 52-week low of $6.23 and a 52-week high of $11.22.

Trending Headlines about BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: BioCryst earned $0.14 per share, topping the $0.09 consensus estimate and improving on $0.06 a year earlier. Revenue was $180.29 million, above the $165.67 million estimate and up 13.1% year over year. The company also raised its guidance. BioCryst Q3 earnings and raised guidance BioCryst third-quarter financial results
• Negative Sentiment: Despite the quarterly earnings beat, BioCryst continues to report a negative net margin and negative return on equity, indicating that profitability remains a concern. BioCryst earnings report

Wall Street Analysts Forecast Growth

BCRX has been the topic of several research reports. Royal Bank Of Canada lowered shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $13.00 to $11.00 in a report on Thursday, September 10th. JPMorgan Chase & Co. boosted their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Finally, Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 24th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.75.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.